ATE537177T1 - Neue 5, 7-disubstituierte ä1, 3üthiazolo ä4, 5- düpyrimidin-2 (3h)-on-derivate und ihre verwendung in der therapie - Google Patents

Neue 5, 7-disubstituierte ä1, 3üthiazolo ä4, 5- düpyrimidin-2 (3h)-on-derivate und ihre verwendung in der therapie

Info

Publication number
ATE537177T1
ATE537177T1 AT07835061T AT07835061T ATE537177T1 AT E537177 T1 ATE537177 T1 AT E537177T1 AT 07835061 T AT07835061 T AT 07835061T AT 07835061 T AT07835061 T AT 07835061T AT E537177 T1 ATE537177 T1 AT E537177T1
Authority
AT
Austria
Prior art keywords
düpyrimidine
3uthiazolo
disubstituted
therapy
derivatives
Prior art date
Application number
AT07835061T
Other languages
English (en)
Inventor
Rolf Johansson
Sofia Karlstroem
Annika Kers
Gunnar Nordvall
Tobias Rein
Can Slivo
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39230456&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE537177(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Application granted granted Critical
Publication of ATE537177T1 publication Critical patent/ATE537177T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Pulmonology (AREA)
  • Cardiology (AREA)
  • Virology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Transplantation (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
AT07835061T 2006-09-29 2007-09-27 Neue 5, 7-disubstituierte ä1, 3üthiazolo ä4, 5- düpyrimidin-2 (3h)-on-derivate und ihre verwendung in der therapie ATE537177T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US82746006P 2006-09-29 2006-09-29
US82812506P 2006-10-04 2006-10-04
PCT/SE2007/000857 WO2008039138A1 (en) 2006-09-29 2007-09-27 Novel 5, 7-disubstituted [1, 3 ] thiazolo [4, 5-d] pyrimidin-2 (3h)-one derivatives and their use in therapy

Publications (1)

Publication Number Publication Date
ATE537177T1 true ATE537177T1 (de) 2011-12-15

Family

ID=39230456

Family Applications (1)

Application Number Title Priority Date Filing Date
AT07835061T ATE537177T1 (de) 2006-09-29 2007-09-27 Neue 5, 7-disubstituierte ä1, 3üthiazolo ä4, 5- düpyrimidin-2 (3h)-on-derivate und ihre verwendung in der therapie

Country Status (22)

Country Link
US (2) US7960395B2 (de)
EP (1) EP2069364B1 (de)
JP (1) JP5422386B2 (de)
KR (1) KR101345085B1 (de)
AR (1) AR063023A1 (de)
AT (1) ATE537177T1 (de)
AU (1) AU2007300748B2 (de)
BR (1) BRPI0717109A2 (de)
CA (1) CA2664789A1 (de)
CL (1) CL2007002813A1 (de)
CO (1) CO6150165A2 (de)
ES (1) ES2377469T3 (de)
HK (1) HK1131389A1 (de)
IL (1) IL197293A0 (de)
MX (1) MX2009003005A (de)
NO (1) NO20091579L (de)
NZ (1) NZ576520A (de)
PE (1) PE20080973A1 (de)
RU (1) RU2441012C2 (de)
TW (1) TW200820973A (de)
UY (1) UY30612A1 (de)
WO (1) WO2008039138A1 (de)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR071036A1 (es) * 2008-03-26 2010-05-19 Astrazeneca Ab Derivados 5, 7-disustituidos de [1, 3]tiazolo[4, 5-d]pirimidin-2 (3h)-ona, una composicion farmaceutica que los comprende y su uso en el tratamiento de enfermedades mediadas por el receptor cx3cr1.
US8476301B2 (en) 2011-09-13 2013-07-02 Eisai R&D Management Co., Ltd. Pyrrolidin-3-ylacetic acid derivative
TWI543975B (zh) 2011-09-13 2016-08-01 Eisai R&D Man Co Ltd Pyrrolidin-3-yl acetic acid derivatives
JP5872105B2 (ja) 2013-03-12 2016-03-01 エーザイ・アール・アンド・ディー・マネジメント株式会社 ピロリジン−３−イル酢酸誘導体の塩およびその結晶
GB201811169D0 (en) * 2018-07-06 2018-08-29 Kancera Ab New compounds

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9802729D0 (sv) 1998-08-13 1998-08-13 Astra Pharma Prod Novel Compounds
SE9903544D0 (sv) 1999-10-01 1999-10-01 Astra Pharma Prod Novel compounds
GB2359081A (en) 2000-02-11 2001-08-15 Astrazeneca Uk Ltd Pharmaceutically active thiazolopyrimidines
AU2001232556A1 (en) * 2000-02-11 2001-08-20 Astrazeneca Ab Pyrimidine compounds and their use as modulators of chemokine receptor activity
SE0101082D0 (sv) 2001-03-27 2001-03-27 Astrazeneca Ab Novel use
GB0221829D0 (en) 2002-09-20 2002-10-30 Astrazeneca Ab Novel compound
GB0221828D0 (en) 2002-09-20 2002-10-30 Astrazeneca Ab Novel compound
MXPA06003792A (es) * 2003-10-07 2006-06-14 Astrazeneca Ab Nuevas 4-amino-tiazolo[4,5-d]-pirimidinas 2-sustituidas, utiles como antagonistas del receptor de quimiocina, especialmente cx3cr1.
WO2006064228A2 (en) * 2004-12-17 2006-06-22 Astrazeneca Ab Thiazolopyramidine compounds for the modulation of chemokine receptor activity
AR053347A1 (es) 2005-04-06 2007-05-02 Astrazeneca Ab Derivados de [1,3]tiazolo[4,5-d]pirimidin-2(3h)-ona 5,7-sustituidos
UA90707C2 (en) 2005-04-06 2010-05-25 Астразенека Аб Novel 5-substituted 7-amino-[1,3]thiazolo[4,5-d]pyrimidine derivatives

Also Published As

Publication number Publication date
AU2007300748B2 (en) 2011-09-08
EP2069364B1 (de) 2011-12-14
JP2010504962A (ja) 2010-02-18
EP2069364A4 (de) 2010-03-24
IL197293A0 (en) 2009-12-24
CO6150165A2 (es) 2010-04-20
TW200820973A (en) 2008-05-16
CL2007002813A1 (es) 2008-04-04
AU2007300748A1 (en) 2008-04-03
CA2664789A1 (en) 2008-04-03
NO20091579L (no) 2009-04-21
AR063023A1 (es) 2008-12-23
NZ576520A (en) 2011-08-26
WO2008039138A1 (en) 2008-04-03
WO2008039138A8 (en) 2009-03-19
KR101345085B1 (ko) 2013-12-31
ES2377469T3 (es) 2012-03-27
JP5422386B2 (ja) 2014-02-19
MX2009003005A (es) 2009-04-01
UY30612A1 (es) 2008-05-02
PE20080973A1 (es) 2008-10-02
HK1131389A1 (en) 2010-01-22
US20080318981A1 (en) 2008-12-25
EP2069364A1 (de) 2009-06-17
RU2441012C2 (ru) 2012-01-27
RU2009109100A (ru) 2010-11-10
US20110105537A1 (en) 2011-05-05
BRPI0717109A2 (pt) 2013-10-08
US7960395B2 (en) 2011-06-14
KR20090057069A (ko) 2009-06-03

Similar Documents

Publication Publication Date Title
ATE543808T1 (de) 5,6-ring-annelierte indolderivate und ihre verwendung
ATE467633T1 (de) 2-aryl-6-phenylimidazoä1,2-aüpyridin-derivate, ihre herstellung und therapeutische verwendung
ATE493396T1 (de) Neue indazolcarboxamide und ihre verwendung
DE502005007106D1 (de) Substituierte phenylaminothiazole und ihre verwendung
ATE370136T1 (de) Benzimidazolderivate und ihre verwendung als antagonisten des a ii rezeptors
ATE553082T1 (de) 5,6-bisaryl-2-pyridin-carboxamid-derivate sowie ihre herstellung und anwendung in therapeutika als urotensin-ii-rezeptor-antagonisten
DE602007004220D1 (de) Neue pyridazinverbindung und ihre verwendung
ATE542816T1 (de) Azabicycloä3.1.0ühexanderivate und ihre verwendung als modulatoren des dopamin-d3- rezeptors
ATE372998T1 (de) 1-aminophthalazinderivate, deren herstellung und deren therapeutische verwendung
ATE487727T1 (de) Neue 5-substituierte 7-amino-ä1,3üthiazoloä4,5- düpyrimidin-2(3h)-onderivate
ATE396185T1 (de) Substituierte 4-alkyl- und 4- alkanoylpiperidinderivate und deren verwendung als neurokininantagonisten
ATE502035T1 (de) 2-amido-4-phenylthiazol-derivate, ihre herstellung und ihre therapeutische verwendung
ATE459608T1 (de) Oxopiperidinderivate, ihre herstellung und therapeutische verwendung
DE602005011593D1 (de) Substituierte diazaspiroä5.5üundecanderivate und deren verwendung als neurokininantagonisten
ATE538125T1 (de) Neue 2-azaindol-derivate, deren herstellung und pharmazeutische verwendung als kinase-inhibitoren
ATE472549T1 (de) Octahydropyrroloä3,4-cüpyrrolderivate und ihre verwendung als antivirale mittel
ATE530527T1 (de) 5,6-bisaryl-2-pyridin-carboxamid-derivate sowie ihre herstellung und anwendung in therapeutika als urotensin-ii-rezeptor-antagonisten
ATE478059T1 (de) Cinnamoylpiperazinderivate und ihre verwendung als par-1-antagonisten
ATE468338T1 (de) Pyrrolochinolinderivate und ihre verwendung als proteinkinasehemmer
ATE537177T1 (de) Neue 5, 7-disubstituierte ä1, 3üthiazolo ä4, 5- düpyrimidin-2 (3h)-on-derivate und ihre verwendung in der therapie
SI1874761T1 (sl) Derivati 4H-1,2,4-triazin-5-onov, njihova priprava in njihova uporaba kot alfa-7-nikotin-acetilholinski receptorji
EP2069365A4 (de) Neue 5,7, 7-disubstituierte [1, 3]thiazolo [4, 5-d]pyrimidin-2 (3h)-amin-derivate und ihre verwendung in der therapie
PL1890695T3 (pl) Zastosowanie 2,5-dipodstawionych pochodnych tiazol-4-onu w lekach
ATE520654T1 (de) Polypyrrol-derivate, ihre herstellung und ihre therapeutische verwendung
ATE448211T1 (de) 1,2,4-triazinderivate, ihre herstellung und ihre verwendung in der humantherapie